Aligning payer and provider strategies with the latest evidence to optimize clinical outcomes for patients with neuromyelitis optica spectrum disorder-Reference-Cited by-同舟云学术

Aligning payer and provider strategies with the latest evidence to optimize clinical outcomes for patients with neuromyelitis optica spectrum disorder

Published:2022-12 Issue:12-a Suppl Volume:28 Page:S3-S27
ISSN:2376-0540
Container-title:Journal of Managed Care & Specialty Pharmacy
language:en
Short-container-title:JMCP

Author:

Wingerchuk Dean M¹,Weinshenker Brian G²,McCormick Dana³,Barron Sasha⁴,Simone Laura⁴,Jarzylo Larissa⁴

Affiliation:

1. Department of Neurology, Mayo Clinic, Phoenix, AZ.

2. Department of Neurology, University of Virginia, Charlottesville.

3. Blue Cross Blue Shield of Texas, Richardson.

4. PRIME Education, Fort Lauderdale, FL.

Publisher

Academy of Managed Care Pharmacy

Subject

Health Policy,Pharmaceutical Science,Pharmacy

Reference135 articles.

1. Neuromyelitis Optica Spectrum Disorder

2. Neuromyelitis optica spectrum disorders: from pathophysiology to therapeutic strategies

3. Monoclonal Antibody Therapies Beyond Complement for NMOSD and MOGAD

4. Epidemiology of Neuromyelitis Optica Spectrum Disorder and Its Prevalence and Incidence Worldwide

5. Update on neuromyelitis optica spectrum disorder

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Preferences for neuromyelitis optica spectrum disorder treatments: A conjoint analysis with neurologists in Spain;Multiple Sclerosis and Related Disorders;2024-08

2. Characterizing mortality in patients with AQP4‐Ab+ neuromyelitis optica spectrum disorder;Annals of Clinical and Translational Neurology;2024-06-17

3. Therapeutic inertia in the management of neuromyelitis optica spectrum disorder;Frontiers in Neurology;2024-02-21

4. Role of serostatus in pediatric neuromyelitis optica spectrum disorders: A nationwide multicentric study;Multiple Sclerosis and Related Disorders;2023-09